Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, komentáře
PubMed
32220013
DOI
10.1111/bjh.16598
Knihovny.cz E-zdroje
- Klíčová slova
- multiple myeloma, serum markers, smoldering multiple myeloma,
- MeSH
- biologické markery MeSH
- doutnající mnohočetný myelom * MeSH
- lidé MeSH
- mnohočetný myelom * diagnóza MeSH
- progrese nemoci MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- komentáře MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- biologické markery MeSH
Department of Hematology Rigshospitalet Copenhagen Denmark
Department of Internal Medicine Herlev Hospital Herlev Denmark
Zobrazit více v PubMed
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New Engl J Med. 2007;356:2582-90.
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-e548.
Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27:941-6.
Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Østergaard B, Gregersen H, et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur J Haematol. 2016;97:303-9.
Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785-9.
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. https://doi.org/10.1038/s41408-018-0077-4.
Pérez-Persona E, Vidriales M-B, Mateo G, García-Sanz R, Mateos M-V, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586-92.
Merz M, Hielscher T, Wagner B, Sauer S, Shah S, Raab MS, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia. 2014;28:1902-8.
Khan R, Dhodapkar M, Rosentha A, Heuck C, Papanikolaou X, Qu P, et al. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG s0120). Haematologica. 2015;100:1214-21.
Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31:4325-32.
Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma. 2013;2215-8.
Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9:1-10.
Mateos M-V, Hernández M-T, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New Engl J Med. 2013;369:438-47.
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020. https://doi.org/10.1038/s41375-020-0718-z.
